ORIC Pharmaceuticals advances prostate cancer drug with Phase 3 trial start planned in 1H 2026

ORIC Pharmaceuticals announced the selection of the Phase 3 dose for rinzimetostat, a prostate cancer drug, and plans to start the Himalayas-1 global registrational trial in the first half of 2026. Early data show rinzimetostat has a strong safety profile and promising efficacy compared to current treatments for metastatic castration-resistant prostate cancer (mCRPC). The company also reported progress with enozertinib for lung cancer and expects multiple clinical updates later in 2026. With $420 million in cash, ORIC is well-funded to support operations into late 2028 and aims to become a multi-asset oncology company.